← Back to Analyst Consensus 
RLMD Buy
RELMADA THERAPEUTICS, INC.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jun 18, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Mar 24, 2026 | Piper Sandler | initiate | — → Overweight | — | 54% |
| Mar 20, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Mar 2, 2026 | LUCID CAPITAL MARKETS | initiate | — → Buy | — | 33% |
| Jan 23, 2026 | Leerink Partners | upgrade | Market Perform → Outperform | $8 | 51% |
| Dec 22, 2025 | Jefferies | initiate | — → Buy | $9 | 52% |
| Nov 19, 2025 | Mizuho | upgrade | Neutral → Outperform | $10 | 52% |
| Dec 5, 2024 | Mizuho | downgrade | Outperform → Neutral | $1 | 52% |
| Dec 4, 2024 | Leerink Partners | downgrade | Outperform → Market Perform | $1 | 51% |
| Jun 5, 2024 | Goldman Sachs | downgrade | Neutral → Sell | $2 | 54% |
| Jun 15, 2023 | Mizuho | reiterate | Buy → Buy | $26 | 52% |
| Jan 23, 2023 | SVB Leerink | maintain | — → Outperform | $10 | — |
| Oct 14, 2022 | Goldman Sachs | downgrade | Buy → Neutral | $8 | 54% |
| Oct 14, 2022 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Oct 13, 2022 | Oppenheimer | downgrade | Outperform → Perform | $0 | 52% |
| Sep 23, 2022 | Goldman Sachs | maintain | — → Buy | $81 | 54% |
| Sep 6, 2022 | Guggenheim | maintain | — → Buy | $60 | 52% |
| May 9, 2022 | Oppenheimer | maintain | — → Outperform | $64 | 52% |
| Mar 24, 2022 | Goldman Sachs | maintain | — → Buy | $53 | 54% |
| Dec 20, 2021 | SVB Leerink | maintain | — → Outperform | $42 | — |
| Nov 18, 2021 | Mizuho | initiate | — → Buy | $50 | 52% |
| Oct 28, 2020 | Goldman Sachs | downgrade | Buy → Neutral | $40 | 54% |
| May 4, 2020 | SunTrust Robinson Humphrey | initiate | — → Buy | $75 | — |
| Apr 21, 2020 | Goldman Sachs | initiate | — → Buy | $63 | 54% |
| Jan 27, 2020 | Jefferies | initiate | — → Buy | $75 | 52% |
| Dec 16, 2019 | Guggenheim | initiate | — → Buy | $64 | 52% |
Price Target Trend
Apr 3, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days